Evidence map›Paper›PMID 39631747›Full record

ArticleVeterinary and comparative oncology2025

Do Pre-Treatment Biopsy Characteristics Predict Early Tumour Progression in Feline Diffuse Large B Cell Nasal Lymphoma Treated With Radiotherapy?

Valerie J Poirier, Valeria Meier, Michelle Turek, Neil Christensen, Jacqueline Bowal, Matthew D Ponzini, Stefan M Keller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary and comparative oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valerie J PoirierDepartment of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.ORCID https://orcid.org/0000-0002-0170-3934
Valeria MeierClinic for Radiation Oncology & Medical Oncology, Vetsuisse Faculty Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-0793-9005
Michelle TurekDepartment of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Neil ChristensenSmall Animal Specialty Hospital, North Ryde, New South Wales, Australia.
Jacqueline BowalDepartment of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Matthew D PonziniDepartment of Public Health Sciences, School of Medicine, University of California, Davis, California, USA.
Stefan M KellerDepartment of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California-Davis, Davis, California, USA.ORCID https://orcid.org/0000-0002-5428-2985

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
Center for Companion Animal Health, University of California, DavisNCATS NIH HHS UL1 TR001860
6 · The paper itself

Abstract

The standard of care treatment for localised feline nasal lymphoma (FeNL) is radiation therapy (RT). Early local or systemic failure occurs in 17%-45% of cats treated with RT with or without chemotherapy. The aim of this study was to determine if pre-treatment biopsy characteristics could predict early tumour progression in FeNL. Inclusion criteria consisted of histologically confirmed FeNL, available paraffin blocks of diagnostic quality, localised to the sinonasal cavity on staging pre-RT, treated with IMRT/IGRT (10 × 4.2 Gy) without chemotherapy and at least 1 year follow-up. All pre-RT biopsies were reviewed and evaluated with CD3, CD20, CD79a, pan-CK and Ki-67 immunohistochemistry and the mitotic activity index was determined. The primary endpoint was progression-free survival (PFS) at 1 year and hazard-ratios (HR) with confidence interval (CI) were calculated. Twenty-eight cats fit the inclusion criteria, and all had diffuse large B-cell lymphoma. Seventeen cats (61%) were progression free at 1 year. Of the 11 cats that progressed in the first year, two had local progression, two had both local and systemic progression and seven had systemic progression. The mitotic index (HR: 1.03, CI 0.9-1.19, p = 0.645), Ki-67 (HR: 1.00, CI 0.98-1.02, p = 0.845) and > 30% of tumour-infiltrating T cells (HR: 0.38, CI 0.09-1.56, p = 0.175) were not significantly associated with PFS. In this uniformly RT treated population of FeNL, none of the evaluated pre-RT histologic parameters could predict early treatment failure.

Indexed as

Cat DiseasesLymphoma, Large B-Cell, DiffuseNose NeoplasmsAnimalsBiopsyCatsDisease ProgressionFemaleMalecatsIMRTKI‐67lymphomatreatment failuretumour‐infiltrating lymphocytes

Identifiers

PMID39631747
PMCPMC11830455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.